Introduction
Cancer immunotherapy using immune checkpoint blockade, particularly 36 antibodies against programmed cell death receptor 1 (PD-1) or its ligand (PD-L1), has suppressive factor would facilitate enhancement of PD-1 blockade therapeutic efficacy 192 only in unresponsive tumors with SIP. 194 To examine whether immune suppressive factors are released from unresponsive 195 tumors, naïve CD8 + T cells were stimulated with anti-(CD3+CD28) mAb-coated beads in 196 the presence of supernatants collected from responsive and unresponsive tumor cell 197 cultures ( Figure 6A ). Proliferation assays (thymidine incorporation and Ki67 detection 198 assays) demonstrated that T cell proliferation was significantly inhibited in the presence 199 of supernatants from LLC or CT26, but not in the presence of supernatants from B16, 200 GL261 or MethA ( Figure 6B and Supplementary Figure S5A Figure S5C) . 203 In addition, different parameters of mitochondrial activation such as cellular ROS 204 and mitochondrial potential were significantly inhibited by the LLC supernatant 205 compared with the B16 and GL261 supernatants ( Figure 6C ). The OCR and the 206 extracellular acidification rate (ECAR), a parameter for glycolytic function, were 207 severely reduced in CD8 + T cells cultured for 48 hours in the presence of LLC 208 supernatants compared with those from B16 and GL261 ( Figure 6D In order to understand the molecular properties of suppressive factors, we 214 performed heat-inactivation to denature protein components and used a dextran-coated 215 charcoal treatment (DCC) to adsorb small molecules in the culture supernatants. As 216 shown in Figure 6F and Supplementary Figure S5E , heat-inactivation of LLC and CT26 217 culture supernatants did not abolish their suppressive activity, whereas removing low 218 molecular weight compounds using the DCC treatment eliminated their suppressive 219 activity, suggesting that the suppressive factor(s) may be comprised of non-proteinaceous 220 small molecules. We further fractionated the supernatant into 'Fraction A (< 3 KDa)' and 221 'Fraction B (3~50 KDa)' and found that Fraction A had almost the same inhibition 222 potential as the total culture supernatants ( Figure 6G and Supplementary Figure S5F ). 223 Again, removing small molecules from Fraction A using the DCC treatment restored the 224 proliferation of CD8 + T cells. 225 Since the tumor-derived soluble suppressive factor(s) are small, non-protein 226 molecules with a size less than 3 kDa, we tested whether known candidates such as 227 adenosine, Prostaglandin E2 (PGE 2 ) and kynurenine show similar activities. However, 228 the suppressive tumors did not express the significant level of related enzymes including 229 CD39, CD73, COX-2, mPGES1 and IDO (Supplementary Figure S6 ).
193

Secretion of immune inhibitory small molecules from SIP-positive tumors
230
Combination of bezafibrate with PD-1 blockade improves survival of mice bearing 231 SIP-positive tumors 232 Since SIP reduced the mitochondrial activity, we examined whether mitochondria 233 activation drug combination can reverse the immune suppression by SIP-positive tumors. 234 As bezafibrate activates mitochondria and synergizes with PD-1 blockade therapy, we 235 first tested whether bezafibrate can reverse the suppression of mitochondrial function and 12 proliferation caused by suppressive factors from the LLC culture supernatants in vitro 237 (Chowdhury et al., 2018). Proliferation and mitochondrial function were regained 238 significantly when bezafibrate was used along with culture supernatant ( Figure 7A ). 239 Encouraged with these in vitro results, we performed PD-1 blockade combinatorial 240 therapy with bezafibrate for LLC tumor-bearing hosts ( Figure 7B ). We found that the 241 tumor-killing effect by the PD-1 blockade was enhanced and mouse survival was 242 increased in the combination therapy ( Figure 7C ). Of note is the fact that the 243 combinatorial treatment could not rescue the B16-bearing host ( Figure 7C ). We observed 244 similar results in tumors on the BALB/c background. The survival of SIP-positive CT26-245 bearing hosts was improved with the combinatorial therapy with bezafibrate 246 (Supplementary Figure S7) . In summary, the SIP effects of unresponsive tumors were 247 partially rescued by a mitochondrial activation chemical, bezafibrate in vitro and in vivo. 249 One of the biggest issues in PD-1 blockade cancer immunotherapy is how to 250 reduce the rate of unresponsiveness. Although there are many unresponsive mechanisms, 251 cancers employ at least two strategies to escape from the immune attack: local or 252 systemic immune suppression. Some reports have suggested "hot tumors" and "cold In this paper, we employed the bilateral tumor inoculation model, which can 259 distinguish local immune suppression including ignorance from systemic immune 260 suppression in vivo, and categorized unresponsive tumors into two groups, with or 261 without SIP. Small molecules with less than 3 kDa size which is released from SIP-262 positive tumors appear to attenuate mitochondria-mediated energy metabolism in T cells. 263 We rule out the known factors such as suppressive cytokines, adenosine, Prostaglandin suggests that tumor recognition by the local tumor area is critical to trigger T cell priming 281 in DLN and to establish the successful tumor-immunity cycle. Therefore, tumors lacking 282 MHC take advantage of the ignorance or escape mechanism not only in the local tumor 283 area, but also in DLN. Given that LLC expresses MHC and is sensitive to the acquired 284 immunity to some extent, it is reasonable that LLC but not B16 is susceptible to the 285 combination therapy.
Discussion
286
Mitochondrial activation is essential for full activation of T cells. In our in vitro 287 assay system for mitochondrial activities, we stimulated naïve CD8 + T cells by anti-288 (CD3+CD28) mAb beads because CD28 in addition to CD3 signal is necessary for robust 289 mitochondria during the proliferation (Klein Geltink et al., 2017). Although our OCR 290 data suggest that the suppressive factor downregulates the mitochondrial activity, ECAR 291 also severely inhibited. Therefore, the suppressive factor may inhibit the glycolysis, 292 resulting in the attenuation of subsequent OXPHOS reactions. This hypothesis agrees 293 with the fact that T cells rely on glycolysis more than OXPHOS when they differentiate from naïve to effector T cells (Menk et al., 2018). Another possible mechanism for 295 suppression of mitochondrial function by the suppressive factors is inhibition of the 296 downstream signals of CD3 and/or CD28 because these 2 signals are necessary for 297 upregulation of glycolysis and OXPHOS in T cells.
298
In this work, we applied bezafibrate to unresponsive LLC or CT26 tumors. We 299 found this combination therapy partially restored the PD-1 blockade effect in accordance 300 with the in vitro assays where bezafibrate partially removed the mitochondrial inhibition 301 by the suppressive factors in the supernatant. This partial effect suggests that under the 302 situation of "brake" induced by the suppressive factors, the "acceleration" by PGC-1α 303 /PPAR activation would not fully work. In order to obtain the maximum benefit, we need 304 to define the suppressive factors and remove the "brake". Our data suggest the possibility 305 of unknown small molecules for suppressive factors. Purification of this small molecule 306 by bio-assays will enable us to identify its structure by mass spectrometry. Once we 307 know such compound, we may be able to find the enzymes responsible for the synthesis 308 of this product and target them for combinatorial treatment. Supplementary Table S1 . The tumor cell lines MethA and GL261 were passaged in vivo 326 once before use in experiments.
327
Monotherapy model using anti-PD-L1 antibody 328 Tumor cells were intradermally (i.d.) injected into the right flank of mice (day 0).
329
Monotherapy with the anti-PD-L1 antibody was started when the tumor size reached 50-330 60 mm 3 (around day 5). Mice were intraperitoneally (i.p.) injected with 80 g of anti-PD-331 L1 mAb (clone 1-111A.4); mAb injection was repeated every fifth day. For untreated mice, an isotype control for the anti-PD-L1 mAb (Rat IgG2a, ) was injected. Tumor 333 sizes were measured every alternate day using a digimatic caliper (Mitutoyo Europe 334 GmbH, Germany) and tumor volume was calculated using the formula for a typical 369 We seeded 0.5 million cells/well in 6-well plates in 4 mL total volume of 370 respective media as recommended by the ATCC. After 48 hours of incubation, we 371 harvested the culture supernatant, centrifuged at 10000 x g for 15 minutes at 22 C, 372 collected the supernatant, and kept it at -80 C for storage. We added culture supernatant 373 one-fourth of the total volume in the well (96-well round bottom plate) throughout the in 374 vitro assays with naïve CD8 + T cells in this work, unless specified.
368
Collection of culture supernatants from different cell lines
375
Thymidine incorporation assay 376 Thymidine solution diluted in spleen RPMI (Basal RPMI media with 10% FCS, 377 1% Penicillin-Streptomycin, 50 μM 2-Mercapto ethanol, L-Glutamine, Na-pyruvate, NEAA) was added to cells and incubated for 4 hours at 37 C in a humidified incubator 379 with 5% CO 2 . After incubation, cells were transferred to a 96-well filter plate followed by 380 addition of scintillation buffer. Thymidine uptake was measured on a Microbeta 2 381 microplate counter (PerkinElmer, # 2450-0120) machine.
382
Heat-inactivation treatment of supernatant: 383 To inactivate the protein component, culture supernatant was boiled for 10 384 minutes at 95 C followed by centrifugation at 10,000 x g for 30 minutes. The 385 supernatant was collected and stored at -80 C for storage.
386
Dextran-coated charcoal (DCC) treatment of supernatant:
387
To remove small molecules, the supernatant was treated with DCC, which 388 removes small molecules (e.g. nucleotides, vitamins, lipids) from the sample by 389 adsorbing them on the surface. To remove small molecules, 12 mg DCC (for 500 L 390 supernatant) was added and incubated for 20 min at 25 C, followed by centrifugation at 391 10,000 x g for 30 minutes. After centrifugation, the supernatant that was free from small 392 molecules was collected. RPMI media and incubated at 37 °C in a 5% CO 2 humidified incubator for 30 min. After 421 incubation, cells were washed twice with D-PBS buffer followed by surface staining.
422
Intranuclear staining 423 For intranuclear staining, cells were fixed and permeabilized using Foxp3 staining kit (Thermo Fisher scientific, Catalog # 00-5523-00) following the manufacturer's 425 instructions. After fixation and permeabilization, cells were incubated with the respective 426 antibody for 15 minutes at 4 C in the dark, followed by washing with FACS buffer 427 (PBS, 0.5-1% BSA or 5-10% FBS, 0.1% NaN3 sodium azide).
428
Intracellular cytokine staining for IFNγ 429 Homogenized tumor mass cells from in vivo treated experimental mice were 430 incubated for 4 hours at 37 °C in a 5% CO 2 humidified incubator. After incubation, Table S2 .
446
Measurement of oxygen consumption rates and extracellular acidification rate
The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) 448 of treated cells were measured using an XF e 96 Extracellular Flux analyzer (Seahorse 449 Biosciences, North Billerica, MA, USA). One day before the experiment, first the XF e 96 450 plate was coated with CellTak solution as per the manufacturer's recommendation. On 451 the day of experiment, all chemicals (e.g. Oligomycin, FCCP and Rotenone/Antimycin 452 A) were prepared in OCR media as per the manufacturer's recommendation and the 453 machine was calibrated using the calibrant buffer in the calibrant plate prior to the 454 experiment. 400 thousand cells per well were seeded in the precoated XF e 96 plate and the 455 OCR/ECAR was measured. Different parameters from the OCR graph were calculated.
456
ATP turnover was defined as follows: (last rate measurement before oligomycin) -
457
(minimum rate measurement after oligomycin injection). Maximal respiration was 458 defined as follows: (maximum rate measurement after FCCP) -(non-mitochondrial 459 respiration). Spare respiratory capacity (SRC) was calculated by subtracting basal 460 respiration from maximal respiration. We measured the ECAR value in the same well, 461 which contained an optimal glucose level so the basal ECAR (or glycolysis) value is the 462 reading we obtained immediately before oligomycin injection. We prepared the assay 463 medium as described in the XF cell Mito Stress Test Kit (Kit 103015-100). The glucose 464 concentration in this medium is 10 mM. In the classical glycolytic assay procedure 465 (glucose-free media) the final concentration of glucose added to the port was 10 mM 466 while measuring flux. The basal ECAR value in this classical method is calculated by 467 subtracting the last rate measurement before the glucose injection from the maximum rate 468 measurement before the oligomycin injection, which gives essentially the same value if 469 calculated by our method. Glycolytic capacity was defined as the rate measured after the oligomycin injection. The glycolytic reserve was defined as follows: (glycolytic capacity) 471 -(basal ECAR value).
472
Statistics 473
Statistical analysis was performed using Prism 6 (GraphPad Software, La Jolla, 474 CA, USA). One-way ANOVA analysis followed by Sidak's multiple comparison test was 475 utilized to analyze three or more variables. To compare two groups, student t test was 476 used. All statistical tests were two-sided assuming parametric data, and a p value of < Supplementary Table S1 . List of mouse cell lines from different genetic backgrounds used in this study.
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